Phaseline

Companies › Perspective Therapeutics

Perspective Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
[212Pb]VMT-α-NET–Phase 1Recurrent Melanoma (Skin); Pancreatic Ductal Adenocarcinoma; Neuroendocrine Tumors UnresectableDec 2027
[203Pb]Pb-PSV359
FAP-targeting radiopharmaceutical with lead-203 for imaging
FAPPhase 1Pancreatic Ductal AdenocarcinomaJan 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05655312[212Pb]VMT-α-NETPhase 1Recurrent Melanoma (Skin)OncologyDec 2027
NCT06710756[212Pb]VMT-α-NETPhase 1Pancreatic Ductal AdenocarcinomaOncologyJan 2028
NCT06710756[203Pb]Pb-PSV359Phase 1Pancreatic Ductal AdenocarcinomaOncologyJan 2028
NCT05636618[212Pb]VMT-α-NETPhase 1Neuroendocrine Tumors UnresectableOncologyNov 2029

From the company's SEC filings

Cash and short-term investments of $202m on 2026-09-30; operating cash outflow about $112m a year; runway about 22 months at that burn, to Jul 2028

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Specialist investors

Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

FAP (1)

Companies with the same targets

Chengdu New Radiomedicine Technology Avacta Life Sciences Blue Earth Diagnostics Novartis Ratio Therapeutics Beijing Biotech SOFIE Philogen BioInvent International Lantheus Medical Imaging

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.